The impact of different antibiotic treatment regimens on mortality in<i>Mycobacterium avium</i>complex pulmonary disease: a population-based cohort study
Sarah K. Brode, Hannah Chung, Michael A. Campitelli, Jeffrey C. Kwong, Rinku Sutradhar, Alex Marchand‐Austin, Kevin Winthrop, Frances Jamieson, et al. (9 authors)
European Respiratory Journal · 2020-05
Abstract
Evidence-based guidelines recommend the combination of macrolide–ethambutol–rifamycin as first-line treatment for Mycobacterium avium complex pulmonary disease (MAC-PD) [1]. Whether this regimen results in improved survival is unknown. No significant difference in mortality among patients treated with different antibiotic regimens for Mycobacterium avium pulmonary disease <https://bit.ly/3abXjDJ> We thank IMS Brogan Inc. for use of their Drug Information Database.
MeSH terms
- Ethambutol
- Medicine
- Mycobacterium avium complex
- Rifamycin
- Rifabutin
- Internal medicine
- Antibiotics
- Cohort
- Regimen
- Rifampicin
- Disease
- Population
- Intensive care medicine